https://www.benzinga.com/general/biotech/24/10/41505575/roches-q3-sales-surge-led-by-ocrevus-vabysmo-urges-regulators-to-block-novo-holdings-16-5b-catale
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent...
rochesalessurgeledocrevus
https://clarivate.com/life-sciences-healthcare/report/emthcg0006-2018-biopharma-multiple-sclerosis-relapsing-remitting-emerging-therapies-ocrevus-ocrelizumab-us-wave-3/
Market Overview Ocrevus is the latest disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United...
multiple sclerosisrelapsing remittingemergingtherapiesocrevus